Leveraging Eurofins’ pharmacology, in-vitro models and ADME capabilities, PharmaResources aims to accelerate drug discovery for its clients in small molecule drug R&D.
Escient Pharmaceuticals has entered the market after closing a $40m Series A financing round – and has contacted Eurofins Discovery for integrated drug discovery services.
Charles River Laboratories recently announced that Alzheimer’s Research UK selected the company to join the Dementia Consortium to help researchers progress projects to in vivo proof of concept.
Insilico Medicine will use its next-generation AI platform to accelerate CRFH’s drug discovery and development efforts – a deal that exemplifies maturation in the market as researchers explore new ways to conduct R&D.
SEngine Precision Medicine raises $5.1m in a Series A investment round to further develop its 3D tumor organoid diagnostic and drug discovery platform.
Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.
The drug discovery and preclinical services company has moved its US office to Kendall Square as it looks to ‘sustainably grow’ its US presence and increase sales in the coming years, says SVP.
As summer heated up, the pharmaceutical industry saw major developments in preclinical models from new software to 3D-printed tissue, all in the name of drug development.
Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.
Schrödinger secures further funding, extends collaboration with Morphic Therapeutic on computational discovery platform for oral integrin drugs for the second time.
Engineered cardiac tissues generated using Tara Biosystems' heart-on-a-chip system predict how patients will respond to a range of drugs, as demonstrated in a recent study with GSK.
Insilico Medicine develops a semi-automated contracting system to ease the collaboration process between AI companies and industry partners in the discovery space.
Recursion Pharmaceuticals plans to partner with big pharma on rare disease programs after raising $121m to build out its machine learning-enabled platform, which draws on an in-house developed dataset to support drug discovery and development.
The global drug discovery market is expected to reach $68bn in 2028, according to a Visiongain report, with revenue gains driven by flexibility, agility, and the ability to innovate, says Evotec executive.
Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Evotec are among the top companies with “AI-friendly” CEOs, according to a report, which suggests that these businesses will prosper driven by a more effective application of AI.
Gilead and HitGen have signed a drug discovery collaboration – one of several recently announced agreements as HitGen sees increased demand for its technology, says CSO.
The industrialized process the industry has developed over the years is not ready for the non-blockbuster environment its entering but AI can help, says Numerate executive.
Medicines Discovery Catapult launches a Virtual R&D Discovery Services platform made up of more than 20 CROs, which will help support small- to medium-sized companies deliver drug discovery projects.
Senator Flake will discuss regulatory guidance impacting innovation and his perspective on the state of the industry during his keynote address at CPhI North America.
Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
Metrion Biosciences looks to partner and move its lead candidate into clinical trials later this year fueled by a funding round which will also see its drug discovery services expand throughout 2019.
Lundbeck extends its research collaboration with the drug discovery services provider Enamine to help “intensify its search for quality lead compounds.”
Evotec AG is partnering with the Mark Foundation for Cancer Research to discover and develop first-in-class therapeutics in oncology using its new drug discovery platform.
Using its proprietary bioprocessing technology, Cellesce is scaling the production of breast organoids for drug discovery research – with plans to expand into other areas of unmet medical need, says CEO.
Optibrium develops software for drug discovery and today announces a collaboration with InfoChem GmbH, a cheminformatics company, to provide users with a computer-aided synthesis design tool.
Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.
People on the move in January include new CEOs at Lonza, Taconic, MaSTherCell, Pii, and Wasdell, among several other c-suite shakeups and new hires as the industry kicks off the New Year.
Though larger pharma companies are investing heavily in biologics, the industry is set to be predominantly focused on small molecules moving forwards, claims CAS MD.
Schrödinger closed an $85m (€74) financing round to support an expansion of its computational platform and drug discovery pipeline for internal and external use.
Elpis Biomed is scaling its proprietary ‘direct cellular reprogramming platform’ – and has its sights set on becoming a global provider of high-quality human cells, with strategic partnerships soon to be announced, says the company’s founder.
SPARC and Schrödinger will collaborate to use Schrödinger’s technological platforms and SPARC’s insights into research therapeutics for neurodegenerative conditions.
Cyclica, a Bayer G4A company, will work with Bayer to advance drug discovery. The collaboration will involve looking further into polypharmacological profiles of small molecules.
The pharmaceutical industry has increasingly been adopting artificial intelligence – which has demonstrated the ability to predict instances of schizophrenia with 74% accuracy.
Charles River is eyeing M&A opportunities in every segment of its business, fueled by global market demand and a “fundamental shift” in the pharmaceutical industry, says CEO.
